2-(2-chlorophenyl)-4-Methyl-5-(pyridin-2-ylMethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione
- Product Name
- 2-(2-chlorophenyl)-4-Methyl-5-(pyridin-2-ylMethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione
- CAS No.
- 955272-06-7
- Chemical Name
- 2-(2-chlorophenyl)-4-Methyl-5-(pyridin-2-ylMethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione
- Synonyms
- AK120765;GKT136901;GKT136901, 10 mM in DMSO;NOX Inhibitor IV, GKT136901;2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6-dione;2-(2-chlorophenyl)-4-Methyl-5-(pyridin-2-ylMethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;1H-Pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, 2-(2-chlorophenyl)-4-methyl-5-(2-pyridinylmethyl)-;2-(2-chlorophenyl)-4-methyl-5-[(pyridin-2-yl)methyl]-1H,2H,3H,5H,6H-pyrazolo[4,3-c]pyridine-3,6-dione;peroxynitrite,scavenger,neurodegeneration,NOX1/4,NADPH,oxidase,inhibit,NOX,NADPH Oxidase,GKT-136901,GKT 136901,nephropathy,anti-inflammatory,GKT136901,stroke,Inhibitor,diabetic
- CBNumber
- CB02598866
- Molecular Formula
- C19H15ClN4O2
- Formula Weight
- 366.8
- MOL File
- 955272-06-7.mol
2-(2-chlorophenyl)-4-Methyl-5-(pyridin-2-ylMethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione Property
- Boiling point:
- 530.2±60.0 °C(Predicted)
- Density
- 1.48±0.1 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- DMF:25.0(Max Conc. mg/mL);68.16(Max Conc. mM)
DMSO:30.0(Max Conc. mg/mL);81.79(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:6):0.14(Max Conc. mg/mL);0.38(Max Conc. mM)
Ethanol:1.0(Max Conc. mg/mL);2.73(Max Conc. mM) - form
- A solid
- pka
- 4.22±0.12(Predicted)
- color
- Off-white to light brown
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H332Harmful if inhaled
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- 5.34032
- Product name
- NOX Inhibitor IV, GKT136901 - CAS 955272-06-7 - Calbiochem
- Purity
- Potent, orally available dual inhibitor of NOX1/NOX4. Blocks NOX-mediated ROS outburst and efficiently scavenges peroxynitrite.
- Packaging
- 10MG
- Price
- $182
- Updated
- 2025/07/31
- Product number
- CS-0021553
- Product name
- GKT136901
- Packaging
- 50mg
- Price
- $200
- Updated
- 2021/12/16
- Product number
- CS-0021553
- Product name
- GKT136901
- Packaging
- 5mg
- Price
- $50
- Updated
- 2021/12/16
- Product number
- CS-0021553
- Product name
- GKT136901
- Packaging
- 10mg
- Price
- $75
- Updated
- 2021/12/16
- Product number
- HCH0356950
- Product name
- 2-(2-CHLOROPHENYL)-4-METHYL-5-(PYRIDIN-2-YLMETHYL)-1H-PYRAZOLO[4,3-C]PYRIDINE-3,6(2H,5H)-DIONE
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $499.32
- Updated
- 2021/12/16
2-(2-chlorophenyl)-4-Methyl-5-(pyridin-2-ylMethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione Chemical Properties,Usage,Production
Uses
GKT136901 is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite. GKT136901 can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 also has anti-inflammatory activity[1][2][3].
Biological Activity
Cell permeable: yes', 'Primary Target
NOX1- and NOX4-containing NADPH oxidase activity', 'Reversible: yes
Synthesis
1217897-99-8
955272-06-7
d) Synthesis of 2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione (Compound (Ia) of formula (II), Scheme 1): an isopropanol solution of sodium isopropoxide was prepared by dissolving sodium (0.082 g, 3.57 mmol, 1 equiv.) in isopropanol (75 mL). To this solution was added methyl [(4E)-1-(2-chlorophenyl)-5-oxo-4-{[(pyridin-2-ylmethyl)amino]ethylidene}-4,5-dihydro-1H-pyrazol-3-yl]acetate (compound of formula (VIII), 1.42 g, 3.57 mmol). The reaction mixture was refluxed for 1 hour and subsequently cooled to room temperature. It was neutralized with 20% aqueous hydrochloric acid (0.59 mL) to pH 7. After removing 50 mL of isopropanol by distillation under reduced pressure, 25 mL of water was added. The reaction flask was placed in a refrigerator overnight and a white precipitate was precipitated. The precipitate was collected by filtration, washed sequentially with water (2 x 5 mL) and cyclohexane, and dried under vacuum to afford the pure product 2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione 1.07 g in 82% yield.1H-NMR (500 MHz, DMSO-d6, ppm) : 2.78 (s, 3H), 5.41 (s, 2H), 5.66 (s, 1H), 7.31-7.28 (m, 1H), 7.32 (d, J=7.9 Hz, 1H), 7.50-7.47 (m, 2H), 7.60-7.56 (m, 1H), 7.66-7.64 (m, 1H), 7.79 (td, J=7.6 ,1.9 Hz, 1H), 8.48 (m, 1H), 10.73 (s, br, 1H).MS (ESI+): 367.9; MS (ESI-): 365.7.
in vivo
GKT136901 (30-90 mg/kg; daily p.o. for 16 weeks) has renoprotective effects in a mouse model of Type 2 diabetes[6].
| Animal Model: | Male db/db and db/m mice (8 weeks)[6] |
| Dosage: | 30, 90 mg/kg |
| Administration: | Daily p.o. for 16 weeks |
| Result: | Reduced albuminuria, thiobarbituric acid-reacting substances (TBARS) and renal ERK1/2 phosphorylation and preserved renal structure in diabetic mice. Had no effect on plasma glucose, BP (blood pressure), and body weight. |
IC 50
NOX1; NOX4
References
[1] Laleu B, et, al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem. 2010 Nov 11;53(21):7715-30. DOI:10.1021/jm100773e
[2] Teixeira G, et, al. Therapeutic potential of NADPH oxidase 1/4 inhibitors. Br J Pharmacol. 2017 Jun;174(12):1647-1669. DOI:10.1111/bph.13532
[3] Schildknecht S, et, al. The NOX1/4 inhibitor GKT136901 as selective and direct scavenger of peroxynitrite. Curr Med Chem. 2014;21(3):365-76. DOI:10.2174/09298673113209990179
[4] Sedeek M, et, al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 2010 Dec;299(6):F1348-58. DOI:10.1152/ajprenal.00028.2010
[5] Hwang JS, et, al. GKT136901 protects primary human brain microvascular endothelial cells against methamphetamine-induced blood-brain barrier dysfunction. Life Sci. 2020 Sep 1;256:117917. DOI:10.1016/j.lfs.2020.117917
[6] Sedeek M, et, al. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond). 2013 Feb;124(3):191-202. DOI:10.1042/CS20120330
2-(2-chlorophenyl)-4-Methyl-5-(pyridin-2-ylMethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione Preparation Products And Raw materials
Raw materials
Preparation Products
2-(2-chlorophenyl)-4-Methyl-5-(pyridin-2-ylMethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione Suppliers
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- +1-708-310-1919 +1-13798911105
- Fax
- 708-557-7486
- sales@invivochem.cn
- Country
- United States
- ProdList
- 6391
- Advantage
- 58
- Tel
- +1-781-999-5354;
- support@targetmol.com
- Country
- United States
- ProdList
- 39035
- Advantage
- 58
- Tel
- --
- Fax
- --
- cayman@caymanchem.com
- Country
- United States
- ProdList
- 6213
- Advantage
- 81
- Tel
- --
- Fax
- --
- sales@combi-blocks.com
- Country
- United States
- ProdList
- 6618
- Advantage
- 69
- Tel
- --
- Fax
- --
- sales@matrixscientific.com
- Country
- United States
- ProdList
- 6632
- Advantage
- 80
View Lastest Price from 2-(2-chlorophenyl)-4-Methyl-5-(pyridin-2-ylMethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione manufacturers
- Product
- 2-(2-chlorophenyl)-4-Methyl-5-(pyridin-2-ylMethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione 955272-06-7
- Price
- US $1.00/KG
- Min. Order
- 1KG
- Purity
- 98% HPLC
- Supply Ability
- 10 Tons
- Release date
- 2020-02-19